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Southeast Asian ovalocytosis is associated 
with increased expression of Duffy antigen 
receptor for chemokines (DARC)
I.J. Woolley, P. Hutchinson, J.C. Reeder, J.W. Kazura, and A. Cortés
The Duffy antigen receptor for chemokines (DARC or Fy glyco-
protein) carries antigens that are important in blood transfusion 
and is the main receptor used by Plasmodium vivax to invade 
reticulocytes. Southeast Asian ovalocytosis (SAO) results from 
an alteration in RBC membrane protein band 3 and is thought to 
mitigate susceptibility to falciparum malaria. Expression of some 
RBC antigens is suppressed by SAO, and we hypothesized that 
SAO may also reduce Fy expression, potentially leading to reduced 
susceptibility to vivax malaria. Blood samples were collected from 
individuals living in the Madang Province of Papua New Guinea. 
Samples were assayed using a flow cytometry assay for expres-
sion of Fy on the surface of RBC and reticulocytes by measuring 
the attachment of a phycoerythrin-labeled Fy6 antibody. Reticu-
locytes were detected using thiazole orange. The presence of the 
SAO mutation was confirmed by PCR. There was a small (approxi-
mately 10%) but statistically significant (p=0.049, Mann-Whitney 
U test) increase in Fy expression on SAO RBC compared with RBC 
from individuals without this polymorphism: mean Fy expres-
sion (mean fluorescence intensity [MFI]) was 10.12 ± 1.22 for SAO 
heterozygotes versus an MFI of 8.95 ± 1.1 for individuals without 
SAO. For reticulocytes the MFI values were 27.61 ± 19.12 for SAO 
heterozygotes and 16.47 ± 3.81 for controls. SAO is associated with 
increased and not decreased Fy6 expression so that susceptibility 
to P. vivax infection is unlikely to be affected. 
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In 1949 Haldane proposed that malaria had a dramatic influence on the human genome, by selecting for ge-netic polymorphisms that were known or suspected to 
protect against malaria.1 Although some of these polymor-
phisms can be detrimental when individuals are homozy-
gous, e.g., sickle cell anemia, their apparent selection in hu-
man populations living in malaria-endemic areas is evidence 
that they offer some protection against death from malaria, 
an infectious disease that continues to kill more than 1 mil-
lion persons annually.2 Critical to this theory is the concept 
of heterozygote advantage. That is, carriage of the mutant 
gene on one member of a chromosomal pair is beneficial 
whereas homozygosity is deleterious. An extreme example 
of heterozygote advantage in Melanesian populations is 
Southeast Asian ovalocytosis (SAO), a hereditary form of 
ovalocytosis that is caused by a 27-base pair deletion in the 
gene encoding the major integral RBC membrane protein 
band 3 (AE1, SLC4A1), leading to a distinctive change in 
RBC morphology.3 SAO is widespread in several popula-
tions of Papua New Guinea (PNG), where its prevalence 
correlates with malaria endemicity and altitude.4 In these 
populations, homozygosity is apparently incompatible with 
full development of the fetus inasmuch as no persons ho-
mozygous for the band 3 mutation have yet been described, 
but heterozygosity confers strong protection against cere-
bral malaria.5,6 Although early studies had suggested that 
the SAO trait may afford some protection against vivax or 
falciparum parasitemia,7–9 other studies did not support 
this hypothesis.10 The mechanism of protection against 
cerebral malaria is not completely understood,11,12 but the 
specific protection against cerebral malaria suggests that it 
may operate by means of alterations in sequestration of in-
fected RBC. However, SAO confers limited or no protection 
against placental malaria, which is also linked to sequestra-
tion of infected RBCs.13,14
 Individuals whose RBCs are negative for expression of 
Duffy antigens illustrate homozygote advantage for vivax 
malaria in that their RBCs are completely refractory to in-
vasion by Plasmodium vivax.15 Historic serologic data sug-
gest expression of some antigens on human RBCs was sup-
pressed by the SAO trait, but expression of Duffy antigens 
did not appear suppressed as determined by the less sensi-
tive serologic instruments available at that time.16 In those 
studies, antibodies of varying specificities were placed in 
tubes using serial dilution, and results were read macro-
scopically with the aid of an eyepiece using a standard-
ized scoring system. In this study, we used molecular and 
cytometric techniques to diagnose SAO and to reexamine 
whether there was a difference in expression of Duffy an-
tigen receptor for chemokines (DARC) between SAO and 
control individuals in the context of possible differential 
susceptibility to infection with different Plasmodium spe-
cies
Materials and Methods
 Blood was collected by venipuncture in CPD anticoag-
ulant or by finger prick using a BD Microtainer (Becton 
Dickinson, San Jose, CA) with EDTA anticoagulant from 
healthy volunteers from two villages, Sempi and Bemlon, 
on the north coast of the Madang Province, PNG. Oral in-
formed consent was obtained after approval for the study 
by the Medical Research Advisory Committee of the PNG 
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Ministry of Health. After collection, samples were kept on 
ice or refrigerated at 4°C. Within 1 week, flow cytometric 
studies were undertaken with antibody to Fy6 (kindly pro-
vided by John Barnwell, CDC, Atlanta, GA). This is a mouse 
monoclonal antibody that attaches to the first extracellular 
domain of the Fy glycoprotein, in an area thought to cor-
respond to the binding site of P. vivax merozoites.17,18 The 
antibody was conjugated directly to a phycoerythrin (PE) 
label (Prozyme, San Leandro, CA) according to the manu-
facturer’s instructions. A 5-µL aliquot of blood was washed 
three times in 50 µL of PBS and pelleted. RBCs were incu-
bated with 50 µL of a 1 in 50 dilution of Fy6 antibody for 15 
minutes at 37°C. Cells were then washed twice in PBS and 
resuspended in thiazole orange (TO) solution according to 
the manufacturer’s specifications (Becton Dickinson). The 
samples were analyzed on a flow cytometer (Mo-Flo, Da-
koCytomation, Fort Collins, CO) equipped with a 70-mW 
air-cooled argon ion laser at 488 nm. TO fluorescence was 
read with a 525-nm bandpass optical filter and PE fluores-
cence with a 570-nm bandpass filter. Compensation was 
applied, and negative fluorescence signals were adjusted 
until they were orthogonal. Forward-scatter, side-scatter, 
and fluorescence data were analyzed. A count of 5000 TO-
positive cells was taken per sample. This was approximately 
1 to 2 percent of the total number of cells assayed for each 
individual. Beads of known immunofluorescence (Immu-
no-Brite, Coulter, Puerto Rico) were used to standardize 
experiments undertaken at different times. Detection of the 
SAO mutation was undertaken using previously described 
PCR methods.19 Experienced microscopists from the PNG 
Institute of Medical Research performed light microscopic 
inspection of Giemsa-stained blood films for malaria para-
sites. Statistical analysis was undertaken by using SPSS 
(Statview 4.51, Abacus Concepts, Berkeley, CA). We have 
used nonparametric testing because we do not have evi-
dence for normal distribution of DARC abundance in the 
surface of SAO erythrocytes.
Results
 Samples from 19 SAO heterozygotes and 20 non-SAO 
donors were examined. Mean age of donors did not dif-
fer significantly between the two groups (mean age, 29.32 
± 13.70 years for SAO heterozygotes versus 26.91 ± 11.80 
years for non-SAO individuals). Four individuals had ma-
laria infection based on inspection of blood smears. One 
SAO and one non-SAO individual had Plasmodium malari-
ae, and two non-SAO donors had Plasmodium falciparum. 
SAO RBC showed increased expression of Fy glycoprotein 
relative to non-SAO RBC as measured by binding of the Fy6 
monoclonal antibody (Table 1). The level of Fy6 antigen 
was also higher in SAO reticulocytes compared with control 
reticulocytes, but the difference was not statistically sig-
nificant (Table 1). Subsequent analysis of the data did not 
suggest the differences were caused by a systemic bias at-
tributable to sex, village of origin, or method of obtaining 
blood (data not shown).
Discussion
 The main finding of this study was that the SAO trait 
does not result in reduced expression of Fy antigen. In fact, 
we observed a 10 percent increase (p=0.049) in Fy antigen 
expression by SAO RBCs when compared with RBCs from 
non-SAO individuals from the same area. This difference 
was significant when expression by all RBC populations 
was evaluated but not when only SAO reticulocytes were 
compared with non-SAO reticulocytes (although a sugges-
tive trend existed). As anticipated, reticulocyte expression 
of Fy6 antigen exceeded RBC expression.20 The reasons for 
the increased RBC Fy6 antigen expression in SAO are un-
clear at present, but it may reflect either a decreased rate of 
loss of Fy6 antigen from the surface of SAO RBC relative to 
control RBC, perhaps in relation to the increased rigidity of 
the SAO cell wall, or differences in the surface area of ovalo-
cytes versus non-SAO RBC. Because there was only a small 
increase in Fy6 antigen expression on SAO RBC and there 
was no statistically significant increase in the reticulocyte 
subpopulation, which is the only subpopulation susceptible 
to infection by P. vivax, it is unlikely that this alteration af-
fects susceptibility to this parasite, although there is other 
in vitro evidence that alterations in numbers of Fy antigens 
expressed may alter that susceptibility.21 It is not surprising 
that the difference in Fy levels was not shown in the paper 
of Booth et al.16 because they were using less sensitive se-
rologic methods or because Fy6 antigen is more available 
or more expressed in SAO ovalocytosis over the antigens 
tested in the previous study. However, their findings with 
respect to other antigens, including Rh polypeptides, have 
subsequently been confirmed by molecular techniques.22
 Fy antigen negativity caused by homozygosity for a pro-
moter mutation that silences transcription of the FY gene23 
is observed in many ethnic groups in sub-Saharan Africa, 
and presumably accounts for the relative lack of vivax ma-
laria in this part of the world. The apparently independent 
emergence of heterozygosity for this same promoter muta-
tion has also been described in the Wosera area of PNG, 
where SAO is rare or nonexistent. There is a need for further 
evaluation of whether other common RBC polymorphisms 
affect Fy antigen expression, especially those that are as-
sociated with changes in RBC shape and surface area. For 
example, α-thalassemia is common in PNG, and in many 
areas, including the Madang Province, nearly all individuals 
have the typical α-globin mutation seen in Melanesians.24 It 
Table 1. Mean fluorescence intensity (± standard deviation) of Fy6 





SAO heterozygotes (N = 19) 27.61 ± 19.12 10.12 ± 1.22
Non-SAO individuals (N = 20) 16.47 ± 3.81 8.95 ± 1.1
P value for difference (Mann-
Whitney U test)
0.65 0.0487
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seems unlikely that this common polymorphism would act 
as a confounding factor in our study on the grounds of bio-
logic plausibility, low likelihood of linkage disequilibrium, 
and very high prevalence in the region (assuming therefore 
more or less equal distribution between SAO and control 
individuals within the population studied). Finally, it will 
be important to determine whether environmental vari-
ables extant in malaria-endemic populations might change 
Fy antigen expression. Another example would be iron defi-
ciency, which is prevalent in PNG and many other malaria-
endemic regions of the world.
 There is evidence that the SAO trait affects several steps 
of the biologic cycle of P. falciparum that may be relevant 
for the selective advantage conferred by this trait against 
malaria. In particular, SAO RBCs are partly resistant to in-
vasion in culture by merozoites of Plasmodium knowlesi 
and several lines of P. falciparum,25,26 and the SAO trait 
also results in altered adhesion of infected RBCs to CD36. 
As with ABO,27 it is likely that the evolutionary pressure ex-
erted by survival with SAO is related to survival of children 
from cerebral malaria before reproductive age. Although Fy 
expression probably affects P. vivax infection,28 this evolu-
tionary pressure is almost certainly caused by P. falciparum 
through its relationship to RBC adhesion.
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